HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

The influence of ICRF-159 and levamisole on the incidence of metastases following local irradiation of a solid tumor.

Abstract
Courses of irradiation consisting of 6000 rad in ten equal fractions over 12 days delivered to KHT sarcomas in mice controlled 55% of the local tumors but 83% of the mice died from metastases. Three strategies to reduce the risk of metastatic spread were tested. The fractionation scheme was changed to deliver the same total dose using a large initial fraction followed by seven equal portions with the same overall time. ICRF-159 was used with the intention of partially synchronizing the tumor growth fraction in a radiosensitive state of the growth cycle and of promoting normalization of the tumor vasculature. Levamisole was used to stimulate the immune system. The combination of ICRF-159 with the eight-fraction radiation course proved to be effective for both increasing local control and decreasing the incidence of metastases. The addition of levamisole did not improve the results obtained with a combination of ICRF-159 and irradiation.
AuthorsD Baker, W Constable, D Elkon, L Rinehart
JournalCancer (Cancer) Vol. 48 Issue 10 Pg. 2179-83 (Nov 15 1981) ISSN: 0008-543X [Print] United States
PMID7296476 (Publication Type: Comparative Study, Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Piperazines
  • Levamisole
  • Razoxane
Topics
  • Animals
  • Female
  • Levamisole (therapeutic use)
  • Mice
  • Neoplasm Metastasis
  • Neoplasm Recurrence, Local
  • Neoplasms (immunology, therapy)
  • Neoplasms, Radiation-Induced (etiology, prevention & control)
  • Piperazines (therapeutic use)
  • Radiotherapy (adverse effects)
  • Radiotherapy Dosage
  • Razoxane (therapeutic use)
  • Risk

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: